Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 598

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Differences in Breast Cancer Survival by Molecular Subtypes in the United States

Howlader, Nadia, Cronin, Kathleen A., Kurian, Allison W., Andridge, Rebecca·2018·Cancer Epidemiology, Biomarkers & Prevention

Abstract

Background: Although incidence rates of breast cancer molecular subtypes are well documented, effects of molecular subtypes on breast cancer–specific survival using the largest population coverage to date are unknown in the U.S. population. Methods: Using Surveillance, Epidemiology and End Results cancer registry data, we assessed survival after breast cancer diagnosis among women diagnosed during 2010 to 2013 and followed through December 31, 2014. Breast cancer molecular subtypes defined by joint hormone receptor [HR, estrogen receptor (ER) and/or progesterone receptor (PR)] and HER2 status were assessed. Multiple imputation was used to fill in missing receptor status. Four-year breast cancer–specific survival per molecular subtypes and clinical/demographic factors were calculated. A Cox proportional hazards model was used to evaluate survival while controlling for clinical and demographic factors. Results: The best survival pattern was observed among women with HR+/HER2− subtype (survival rate of 92.5% at 4 years), followed by HR+/HER2+ (90.3%), HR−/HER2+ (82.7%), and finally worst survival for triple-negative subtype (77.0%). Notably, failing to impute cases with missing receptor status leads to overestimation of survival because those with missing receptor status tend to have worse prognostic features. Survival differed substantially by stage at diagnosis. Among de novo stage IV disease, women with HR+/HER2+ subtype experienced better survival than those with HR+/HER2− subtype (45.5% vs. 35.9%), even after controlling for other factors. Conclusions: Divergence of survival curves in stage IV HR+/HER2+ versus HR+/HER2− subtype is likely attributable to major advances in HER2-targeted treatment. Impact: Contrary to conventional thought, HR+/HER2+ subtype experienced better survival than HR+/HER2− in advanced-stage disease. Cancer Epidemiol Biomarkers Prev; 27(6); 619–26. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-17-0627

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 598

Metadata

Authors
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2018-05-31
Volume
27
Issue
6
Pages
619-626
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W2795120383
Cited by
598
References
33
FWCI
11.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differences in Breast Cancer Survival by Molecular Subtypes in the United States. https://app.cochat.ai/papers/10.1158/1055-9965.epi-17-0627
The paper
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018). Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-17-0627

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.